Sustained consumer demand for GLP-1 receptor agonist therapies has created persistent supply constraints, prompting pharmaceutical developers to aggressively deploy capital into manufacturing infrastructure. Fill-finish capacity remains the primary operational bottleneck.
Contract Manufacturing Expansion
Leading pharmaceutical firms are acquiring dedicated contract development and manufacturing organization (CDMO) facilities to secure fill-finish lines. Analysts project that global production capacity will require double-digit annual growth rates through 2028 to satisfy market demand.